1075 related articles for article (PubMed ID: 10537299)
21. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
22. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor as a marker of tumor endothelium.
Brekken RA; Huang X; King SW; Thorpe PE
Cancer Res; 1998 May; 58(9):1952-9. PubMed ID: 9581838
[TBL] [Abstract][Full Text] [Related]
25. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice.
Kamiyama M; Ichikawa Y; Ishikawa T; Chishima T; Hasegawa S; Hamaguchi Y; Nagashima Y; Miyagi Y; Mitsuhashi M; Hyndman D; Hoffman RM; Ohki S; Shimada H
Cancer Gene Ther; 2002 Feb; 9(2):197-201. PubMed ID: 11857038
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
Lin P; Sankar S; Shan S; Dewhirst MW; Polverini PJ; Quinn TQ; Peters KG
Cell Growth Differ; 1998 Jan; 9(1):49-58. PubMed ID: 9438388
[TBL] [Abstract][Full Text] [Related]
27. Flk-1 as a target for tumor growth inhibition.
Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
[TBL] [Abstract][Full Text] [Related]
29. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
30. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J
Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
[TBL] [Abstract][Full Text] [Related]
32. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Okazaki T; Nishihara S; Arai K; Yamaguchi S; Shibuya M; Nakaike S; Tanaka M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):16-24. PubMed ID: 15064856
[TBL] [Abstract][Full Text] [Related]
33. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
35. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
37. The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
Giatromanolaki A; Sivridis E; Athanassou N; Zois E; Thorpe PE; Brekken RA; Gatter KC; Harris AL; Koukourakis IM; Koukourakis MI
J Pathol; 2001 May; 194(1):101-8. PubMed ID: 11329148
[TBL] [Abstract][Full Text] [Related]
38. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
39. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
